2nd Annual MarketsandMarkets

Next Gen Immuno-Oncology Congress

September 19 - 20, 2019

Hilton Garden Inn Philadelphia Center City

Avail Your Ticket Avail
Your Ticket
Become A Sponsor Become
A Sponsor
Become A Speaker Become
A Speaker

45+

Speakers

250+

Attendees

7+

Sessions

EVENT OVERVIEW

The next step towards changing treatment paradigms in immuno-oncology

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.

Tag Line
With more than 45 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy  
Tag Line
Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.
Tag Line
A platform to meet experts from Pharma, bio-pharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

After our successful edition last year, we are coming up with the “2nd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress” on 19-20 September, Philadelphia, USA which will gather academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.

WHAT TO EXPECT

  • Updates in development of monoclonal Abs and bispecific Abs
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments

  • Targeted Antibodies and Combinations
  • Pre-clinical & Translational Immuno-Oncology Developments
  • New Antibody Formats
  • New Immune Checkpoints for Immunotherapy

  • Find out new case studies of antibody projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you

Expression #1 of SELECT list is not in GROUP BY clause and contains nonaggregated column 'cnceventswithcrm.s.id' which is not functionally dependent on columns in GROUP BY clause; this is incompatible with sql_mode=only_full_group_by